• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单中心住院及门诊患者下肢动脉疾病的阿片类药物使用情况

Single-Center In-Hospital and Outpatient Opioid Use for Lower Extremity Arterial Disease.

作者信息

Fan Xuanjia, Graziane Nicholas M, Castello Ramirez Maria Camila, Stella Salvatore L, Karunanayaka Prasanna, Ruiz-Velasco Victor, Adhikary Sanjib, Flohr Tanya

机构信息

Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, USA.

Vascular Surgery, Penn State Heart and Vascular Institute, Penn State University College of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, USA.

出版信息

Cureus. 2024 May 9;16(5):e59963. doi: 10.7759/cureus.59963. eCollection 2024 May.

DOI:10.7759/cureus.59963
PMID:38726358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11080959/
Abstract

INTRODUCTION

The pain associated with lower extremity arterial disease is difficult to treat, even with lower extremity revascularization. We sought to evaluate in-hospital and post-operative opioid usage in patients with different disease severities and treatments for lower extremity vascular disease.

METHODS

A retrospective review was performed for all hospital encounters for patients with an International Classification of Diseases (ICD) code consistent with lower extremity arterial disease admitted to a single center between January 2018 and March 2023. Cases included patients admitted to the hospital with a primary diagnosis of lower extremity arterial disease. These patients were subdivided based on disease severity, treatment type, and comorbid diagnosis of diabetes mellitus. The analysis focused on in-hospital opioid use frequency and dosage among these patients. The control group (CON) included encounters for patients admitted with a secondary diagnosis of lower extremity atherosclerotic disease. A total of 438 patients represented by all the analyzed encounters were then reviewed for the number and type of vascular procedures performed as well as opioid use in the outpatient setting for one year.

RESULTS

Critical limb ischemia (CLI) encounters were more likely to use opioids as compared to the CON and peripheral arterial disease (PAD) without rest pain, ulcer or gangrene groups (CLI 67.9% (95% CI: 63.6%-71.6%) versus CON 52.1% (95% CI: 48.5%-55.7%), < 0.001 and CLI 67.9% (95% CI: 63.6%-71.6%) versus PAD 50.2% (95% CI: 42.6%-57.4%), < 0.001). Opioid use was also more common in encounters for gangrene and groups treated with revascularization (REVASC) and amputation (AMP) as compared to CON (gangrene 74.5% (95% CI: 68.5%-82.1%) versus CON 52.1% (95% CI: 48.5%-55.7%), < 0.01; REVASC 58.3% (95% CI: 57.3%-66.4%) versus CON 52.1% (95% CI: 48.5%-55.7%), =0.01; and AMP 72.3% (95% CI: 62.1%-74.0%) versus CON 52.1% (95% CI: 48.5%-55.7%), < 0.01). Significantly increased oral opioid doses per day (MME/day) were not noted for any of the investigated groups as compared to the CON. In the outpatient setting, 186 (42.5% (95% CI: 37.2%-46.4%)) patients were using opioids one month after the most recent vascular intervention. By one year, 31 (7.1% (95% CI: 1.30%-7.70%)) patients were still using opioids. No differences in opioid usage were noted for patients undergoing single versus multiple vascular interventions at one year. Patients undergoing certain vascular surgery procedures were more likely to be using opioids at one year.

CONCLUSION

Patients with CLI and gangrene as well as those undergoing vascular treatment have a greater frequency of opioid use during hospital encounters as compared to those patients with less severe disease and undergoing conservative management, respectively. However, these findings do not equate to higher doses of opioids used during hospitalization. Patients undergoing multiple vascular procedures are not more likely to be using opioids long-term (at one year) as compared to those patients treated with single vascular procedures.

摘要

引言

与下肢动脉疾病相关的疼痛难以治疗,即使进行了下肢血管重建术。我们试图评估不同疾病严重程度和接受不同下肢血管疾病治疗的患者在住院期间和术后的阿片类药物使用情况。

方法

对2018年1月至2023年3月期间在单一中心住院、国际疾病分类(ICD)编码与下肢动脉疾病一致的所有患者的医院诊疗记录进行回顾性分析。病例包括以下肢动脉疾病为主要诊断入院的患者。这些患者根据疾病严重程度、治疗类型和糖尿病合并诊断进行细分。分析重点在于这些患者住院期间阿片类药物的使用频率和剂量。对照组(CON)包括以下肢动脉粥样硬化疾病为次要诊断入院的患者。然后对所有分析诊疗记录所代表的438例患者进行了为期一年的门诊血管手术数量和类型以及阿片类药物使用情况的评估。

结果

与对照组以及无静息痛、溃疡或坏疽的外周动脉疾病(PAD)组相比,严重肢体缺血(CLI)患者更有可能使用阿片类药物(CLI为67.9%(95%置信区间:63.6%-71.6%),对照组为52.1%(95%置信区间:48.5%-55.7%),<0.001;CLI为67.9%(95%置信区间:63.6%-71.6%),PAD为50.2%(95%置信区间:42.6%-57.4%),<0.001)。与对照组相比,坏疽患者以及接受血管重建术(REVASC)和截肢术(AMP)治疗的患者中阿片类药物的使用也更为常见(坏疽患者为74.5%(95%置信区间:68.5%-82.1%),对照组为52.1%(95%置信区间:48.5%-55.7%),<0.01;REVASC为58.3%(95%置信区间:57.3%-66.4%),对照组为52.1%(95%置信区间:48.5%-55.7%),=0.01;AMP为72.3%(95%置信区间:62.1%-74.0%),对照组为52.1%(95%置信区间:48.5%-55.7%),<0.01)。与对照组相比,任何研究组均未发现每日口服阿片类药物剂量(吗啡毫克当量/天)显著增加。在门诊环境中,186例(42.5%(95%置信区间:37.2%-46.4%))患者在最近一次血管干预后一个月使用阿片类药物。到一年时,31例(7.1%(95%置信区间:1.30%-7.70%))患者仍在使用阿片类药物。在一年时,接受单次与多次血管干预的患者在阿片类药物使用方面未发现差异。接受某些血管外科手术的患者在一年时更有可能使用阿片类药物。

结论

与疾病较轻且接受保守治疗的患者相比,CLI和坏疽患者以及接受血管治疗的患者在住院期间使用阿片类药物的频率更高。然而,这些发现并不等同于住院期间使用更高剂量的阿片类药物。与接受单次血管手术治疗的患者相比,接受多次血管手术的患者在长期(一年)使用阿片类药物方面并无更高可能性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6620/11080959/5f3feec5c544/cureus-0016-00000059963-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6620/11080959/5f3feec5c544/cureus-0016-00000059963-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6620/11080959/5f3feec5c544/cureus-0016-00000059963-i01.jpg

相似文献

1
Single-Center In-Hospital and Outpatient Opioid Use for Lower Extremity Arterial Disease.单中心住院及门诊患者下肢动脉疾病的阿片类药物使用情况
Cureus. 2024 May 9;16(5):e59963. doi: 10.7759/cureus.59963. eCollection 2024 May.
2
Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.下肢外周动脉疾病的支架置入术:一项基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(18):1-88. Epub 2010 Sep 1.
3
Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease.男性和女性下肢外周动脉疾病行血运重建或截肢治疗的表现、治疗和结局差异。
J Vasc Surg. 2014 Feb;59(2):409-418.e3. doi: 10.1016/j.jvs.2013.07.114. Epub 2013 Sep 29.
4
Association of opioid use and peripheral artery disease.阿片类药物使用与外周动脉疾病的关联。
J Vasc Surg. 2019 Oct;70(4):1271-1279.e1. doi: 10.1016/j.jvs.2018.12.036. Epub 2019 Mar 25.
5
Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus.糖尿病患者和非糖尿病患者下肢血管腔内血运重建后的主要肢体结局
J Endovasc Ther. 2017 Jun;24(3):376-382. doi: 10.1177/1526602817705135. Epub 2017 Apr 25.
6
Perioperative Outcomes of Lower Extremity Revascularization for Rest Pain and Tissue Loss.下肢血运重建治疗静息痛和组织缺损的围手术期结局
Ann Vasc Surg. 2020 Jul;66:493-501. doi: 10.1016/j.avsg.2019.11.019. Epub 2019 Nov 19.
7
Outcomes of open and endovascular lower extremity revascularization in active smokers with advanced peripheral arterial disease.患有晚期外周动脉疾病的活跃吸烟者进行开放性和血管腔内下肢血管重建术的结果。
J Vasc Surg. 2017 Jun;65(6):1680-1689. doi: 10.1016/j.jvs.2017.01.025.
8
Opioid use in patients with peripheral arterial disease undergoing lower extremity bypass.外周动脉疾病患者下肢旁路术后的阿片类药物使用。
J Vasc Surg. 2022 Mar;75(3):998-1007. doi: 10.1016/j.jvs.2021.08.104. Epub 2021 Oct 1.
9
The impact of isolated tibial disease on outcomes in the critical limb ischemic population.孤立性胫骨疾病对严重肢体缺血人群治疗结果的影响。
Ann Vasc Surg. 2010 Apr;24(3):349-59. doi: 10.1016/j.avsg.2009.07.034. Epub 2010 Jan 4.
10
Opioid utilization after lower extremity amputation for peripheral vascular disease and discharge prescribing recommendations.外周血管疾病下肢截肢术后阿片类药物的使用及出院处方建议
Vascular. 2023 Oct;31(5):954-960. doi: 10.1177/17085381221097163. Epub 2022 May 4.

本文引用的文献

1
Are opioids effective analgesics and is physiological opioid dependence benign? Revising current assumptions to effectively manage long-term opioid therapy and its deprescribing.阿片类药物是否是有效的镇痛药,生理性阿片类药物依赖是否良性?修正当前假设,以有效管理长期阿片类药物治疗及其停药。
Br J Clin Pharmacol. 2024 Dec;90(12):2962-2976. doi: 10.1111/bcp.15972. Epub 2023 Dec 26.
2
Association Between Complications after Vascular Surgery and Prolonged Postoperative Opioid Use.血管手术后并发症与术后长期使用阿片类药物之间的关联。
Ann Vasc Surg. 2024 Jan;98:274-281. doi: 10.1016/j.avsg.2023.08.008. Epub 2023 Oct 5.
3
Opioid utilization after lower extremity amputation for peripheral vascular disease and discharge prescribing recommendations.
外周血管疾病下肢截肢术后阿片类药物的使用及出院处方建议
Vascular. 2023 Oct;31(5):954-960. doi: 10.1177/17085381221097163. Epub 2022 May 4.
4
Opioid use in patients with peripheral arterial disease undergoing lower extremity bypass.外周动脉疾病患者下肢旁路术后的阿片类药物使用。
J Vasc Surg. 2022 Mar;75(3):998-1007. doi: 10.1016/j.jvs.2021.08.104. Epub 2021 Oct 1.
5
Prevalence of chronic opioid use in patients with peripheral arterial disease undergoing revascularization.接受血管重建术的外周动脉疾病患者中慢性阿片类药物使用的患病率。
J Vasc Surg. 2022 Jan;75(1):186-194. doi: 10.1016/j.jvs.2021.07.236. Epub 2021 Aug 31.
6
Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature.非甾体抗炎药导致的肾脏损伤——是神话还是事实?对部分文献的综述。
Pharmacol Res Perspect. 2021 Aug;9(4):e00817. doi: 10.1002/prp2.817.
7
Endovascular surgery is not protective against new persistent opioid use development compared to open vascular surgery.与开放血管手术相比,血管内手术并不能预防新的持续性阿片类药物使用的发展。
Vascular. 2022 Aug;30(4):728-738. doi: 10.1177/17085381211024514. Epub 2021 Jun 15.
8
Patient-Reported Outcomes After Opioid-Sparing Surgery Compared With Standard of Care.阿片类药物节约手术后的患者报告结果与标准治疗相比。
JAMA Surg. 2021 Mar 1;156(3):286-287. doi: 10.1001/jamasurg.2020.5646.
9
Association of opioid use and peripheral artery disease.阿片类药物使用与外周动脉疾病的关联。
J Vasc Surg. 2019 Oct;70(4):1271-1279.e1. doi: 10.1016/j.jvs.2018.12.036. Epub 2019 Mar 25.
10
Peripheral artery disease: epidemiology and global perspectives.外周动脉疾病:流行病学和全球视角。
Nat Rev Cardiol. 2017 Mar;14(3):156-170. doi: 10.1038/nrcardio.2016.179. Epub 2016 Nov 17.